Evidence map›Paper›PMID 41634435›Full record

ArticleAnnals of hematology2026

Molecular devolution in chronic myelomonocytic leukemia during treatment with decitabine/cedazuridine: A case report.

Klaus Geissler, Gerlinde Mitterbauer-Hohendanner, Roland Jäger

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Klaus GeisslerMedical School, Sigmund Freud Private University of Vienna, Vienna, Austria. geissler.klaus@gmx.at.
Gerlinde Mitterbauer-HohendannerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Roland JägerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral decitabine/cedazuridine has been studied in chronic myelomonocytic leukemia (CMML) recently but the molecular changes during this treatment have not been reported so far. We report a CMML patient who was treated with oral decitabine/cedazuridine and showed a stepwise loss of KRAS mutation and trisomy 8 while the TET2 mutated clone gradually increased eventually resulting in clonal hematopoiesis. This case report highlights the disease modifying potential of this treatment in single CMML patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Myelomonocytic, ChronicUridineAgedChromosomes, Human, Pair 8Clonal HematopoiesisDecitabineDioxygenasesDNA-Binding ProteinsFemaleHumansMutationProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)TrisomycedazuridineDecitabineDioxygenasesDNA-Binding ProteinsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)TET2 protein, humanUridineCase reportChronic myelomonocytic leukemiaClonal hematopoiesisDecitabine/cedazuridineDisease modifying potential

Identifiers

PMID41634435
PMCPMC12868106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.